Biotech

News

Kyverna prices its IPO, seeking $319m for its cell therapies

Kyverna Therapeutics has announced the pricing of its initial public offering, and in another sign of the improving biotech financing environment has raised its target pro

R&D

Brighter times ahead for biotech in 2024?

The biotech industry experienced heady highs in early 2021, but has since suffered from a tight financial climate that has brought bankruptcies and widespread redundancies.

R&D

A clearer harmony and attractiveness for EU Clinical Trials ...

EU Clinical Trials Regulation (EU CTR) has been a hot topic for a little while now.

News

Vera prices $250m offer, and other biotech financings

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (I

R&D

Making connections and getting noticed as a biotech start-up...

A thriving start-up ecosystem is essential to the health of the modern life sciences industry, as it provides an incubator for innovative ideas that might be too high-risk for larger, more

Digital